<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289847</url>
  </required_header>
  <id_info>
    <org_study_id>GMX04</org_study_id>
    <secondary_id>IND 12569</secondary_id>
    <nct_id>NCT01289847</nct_id>
  </id_info>
  <brief_title>A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency</brief_title>
  <official_title>A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Products Laboratory</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Products Laboratory</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine the efficacy of Gammaplex by measuring the number of
      serious acute bacterial infections during treatment with Gammaplex over a 12 month period.
      The secondary objectives are to assess the safety and tolerability of Gammaplex and to
      compare the data collected from adult subjects with PID from the GMX01 study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects with serious, acute, bacterial infections as a measure of efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Efficacy</measure>
    <time_frame>From week 15 onwards</time_frame>
    <description>Number and proportion of subjects who maintain trough IgG levels at least as high as the average of the 2 previous trough levels before the first Gammaplex infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days off school</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Visits to physicians and/or emergency room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days on therapeutic antibiotics</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Primary Immune Deficiency Disorders</condition>
  <condition>Common Variable Immunodeficiency</condition>
  <condition>X-linked Agammaglobulinemia</condition>
  <condition>Hyper-IgM Syndrome</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <arm_group>
    <arm_group_label>Gammaplex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gammaplex</intervention_name>
    <description>GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
    <arm_group_label>Gammaplex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is between the ages of or is equal to 2 and 16 years of age, of either
             sex, belonging to any ethnic group, and above a minimum weight of 10 kg. This weight
             is based on the amount of blood required for testing.

          -  The subject has a primary immunodeficiency disease, which has as a significant
             component of hypogammaglobulinemia and/or antibody deficiency (e.g. common variable
             immunodeficiency, X-linked and autosomal forms of agammaglobulinemia, hyper-IgM
             syndrome, Wiskott-Aldrich Syndrome). NB Isolated deficiency of a single IgG subclass,
             or of specific antibodies without hypogammaglobulinemia per se, does not qualify for
             inclusion.

          -  Subjects already receiving IGIV replacement therapy require the following before their
             first infusion of Gammaplex:

          -  Documented IGIV dose(s) and treatment intervals for the last 2 consecutive routine
             IGIV treatments (one of which can be the screening visit result). The previous doses
             should also meet the following conditions before study entry: Have not changed by ±
             50% of the mean dose for at least 3 months; be between 300 and 800 mg/kg/infusion; be
             given every 21-28 days, inclusive; be a licensed or investigational product (Phase III
             or IIIb).

          -  Documented previous IgG trough levels for the last 2 consecutive routine IGIV
             treatments for the last 2 consecutive routine IGIV treatments: Maintained at least 300
             mg/dL above baseline serum IgG levels (defined as before initiation of any gamma
             globulin treatment for that subject); must be more than/equal to 600 mg/dL.

          -  If a subject is a female of child-bearing potential, she must have a negative result
             on an HCG-based pregnancy test.

          -  If a subject is a female who is or becomes sexually active, she must practice
             contraception by using a method of proven reliability for the duration of the study.

          -  The subject is willing to comply with all aspects of the protocol, including blood
             sampling, for the duration of the study.

          -  The subject, if old enough (generally 6 years to 16), has signed a Child Assent Form
             and the subject's parent or legal guardian has signed the Informed Consent Form, both
             approved by the IEC/IRB.

        Exclusion Criteria:

          -  Has not been treated with IGIV (treatment naive subject)

          -  The subject has a history of any severe anaphylactic reaction to blood or any
             blood-derived product.

          -  The subject is known to be intolerant to any component of Gammaplex, such as sorbitol
             (i.e. intolerance to fructose).

          -  The subject has selective IgA deficiency, history of reaction to products containing
             IgA, or has a history of antibodies to IgA.

          -  Subjects who have completed the study and subjects who have withdrawn cannot
             participate in the study for a second time.

          -  The subject is currently receiving, or has received, any investigational agent, other
             than an immune serum globulin (ISG) preparation that is being evaluated in a Phase III
             or IIIb study, within the prior 3 months.

          -  The subject has been exposed to blood or any blood product or derivative within the
             last 6 months, other than a commercially available IGIV or other forms of commercially
             available and licensed ISG. If an unlicensed ISG product that is in Phase III or IIIb
             has been given, the subject cannot be infused with Gammaplex until 20 days after the
             last dose was given.

          -  The subject is pregnant or is nursing.

          -  The subject, at screening, has levels greater than 2.5 times the upper limit of normal
             as defined at the central laboratory of any of the following: (Alanine transaminase
             (ALT); Aspartate transaminase (AST) Lactate dehydrogenase (LDH)).

          -  The subject has a severe renal impairment (defined as serum creatinine greater than 2
             times the upper limit of normal or BUN greater than 2.5 times the upper limit of
             normal for the range of the laboratory doing the analysis); the subject is on
             dialysis; the subject has a history of acute renal failure.

          -  The subject is known to abuse alcohol, opiates, psychotropic agents, or other
             chemicals or drugs, or has done so within the past 12 months.

          -  The subject has a history of DVT, or thrombotic complications of IGIV therapy.

          -  The subject suffers from any acute or chronic medical condition (e.g. renal disease or
             predisposing conditions for renal disease, or protein losing state) that, in the
             opinion of the investigator, may interfere with the conduct of the study.

          -  The subject has an acquired medical condition, such as, chronic or recurrent
             neutropenia (ANC &lt; 1000 x 109/L) or AIDS known to cause secondary immune deficiency,
             or is post or recovering from hematopoietic stem cell transplantation.

          -  The subject is receiving the following medication: Systemic long-term corticosteroids
             (i.e. not intermittent or burst, daily, &gt;1 mg of prednisone equivalent/kg/day).

          -  The subject is receiving Immunosuppressive or Immunomodulatory drugs.

          -  The subject has non-controlled arterial hypertension.

          -  The subject has anemia (hemoglobin &lt;10 g/dL) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim J. Aldwinckle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697.</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Reseach Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy &amp; Asthma Center, PC</name>
      <address>
        <city>Atlanta,</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago,</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Immunology Clinic, P.A</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond, VA</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Niňos Roberto del Río</name>
      <address>
        <city>Santiago</city>
        <zip>8380418</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Safra Children's Hospital, Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <results_first_submitted>December 8, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2014</results_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Immune Deficiency Disorders</keyword>
  <keyword>Common Variable Immunodeficiency</keyword>
  <keyword>X-linked agammaglobulinemia</keyword>
  <keyword>Hyper-IgM syndrome</keyword>
  <keyword>Wiskott-Aldrich Syndrome</keyword>
  <keyword>Immunoglobulins</keyword>
  <keyword>Bacterial Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Hyper-IgM Immunodeficiency Syndrome, Type 1</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First enrollment: 06 April 2011; Last Subject completed 23 April 2014; Nine recruiting sites globally: United States (US) (seven sites), Chile (one site) and Israel (one site)</recruitment_details>
      <pre_assignment_details>This was a Phase IV, multicentre, open-label, non-randomised study. All enrolled subjects received study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gammaplex</title>
          <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient could not comply with visits</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gammaplex</title>
          <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 to 5 year age group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 11 year age group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 16 year age group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Number of subjects with serious, acute, bacterial infections as a measure of efficacy</description>
        <time_frame>12 months</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of subjects with serious, acute, bacterial infections as a measure of efficacy</description>
          <population>Intent to Treat (ITT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For the primary efficacy analysis, the SABI rate for GAMMAPLEX and the upper bound of its one-sided 99% confidence interval (CI) were estimated by using the exact method for a one-sample Poisson rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>one-sample Poisson rate</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Efficacy</title>
        <description>Number and proportion of subjects who maintain trough IgG levels at least as high as the average of the 2 previous trough levels before the first Gammaplex infusion</description>
        <time_frame>From week 15 onwards</time_frame>
        <population>Seven subjects (28.0%) maintained trough IgG levels at all visits that were at least as high as the average of the two previous levels before the first infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy</title>
          <description>Number and proportion of subjects who maintain trough IgG levels at least as high as the average of the 2 previous trough levels before the first Gammaplex infusion</description>
          <population>Seven subjects (28.0%) maintained trough IgG levels at all visits that were at least as high as the average of the two previous levels before the first infusion</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>one-sample Poisson method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Efficacy</title>
        <description>Number of days off school</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy</title>
          <description>Number of days off school</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Efficacy</title>
        <description>Number of days in hospital</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy</title>
          <description>Number of days in hospital</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Efficacy</title>
        <description>Visits to physicians and/or emergency room</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy</title>
          <description>Visits to physicians and/or emergency room</description>
          <units>visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Efficacy</title>
        <description>Number of days on therapeutic antibiotics</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gammaplex</title>
            <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy</title>
          <description>Number of days on therapeutic antibiotics</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="28.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were documented from the date Informed Consent Form or Assent was signed until 30 days after the last dose of Gammaplex was infused.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gammaplex</title>
          <description>Gammaplex: GAMMAPLEX 5g/100 mL, dose is 300–800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Gastroenterirtis (AGE)</sub_title>
                <description>Three days prior to hospital admission the subject experienced watery diarrhea and vomiting. It was reported that the subject would not eat or drink and had a one-time fever of 38.1 degrees celsius. Resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>left lower lobe pneumonia</sub_title>
                <description>A chest X-ray revealed a 4 cm retrocardiac left lung base infiltrate. Laboratory results included a WBC count of 26.4 × 109/L (ref range 4.8-10.8 × 109/L), band neutrophils 23% (ref range 50-80%) and lymphocytes 6% (ref range 20-50%). Resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>left lower lobe pneumonia</sub_title>
                <description>The subject was hospitalised with a fever (101.8°F), tachycardia, dyspnoea, hypoxia and vomiting. No bacterial aetiology was identified by blood cultures. Resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title vocab="medDRA 8.1">Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (8.1)">Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="13" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Diastolic hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the PI and Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results.
Publication of Study results will be allowed only with prior written approval from Sponsor. At the request of Sponsor, the Institution and/or Investigator shall delete any Confidential Information pertaining to Sponsor's Inventions from any proposed publications prior to submitting or presenting the materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Medical Affairs</name_or_title>
      <organization>Bio Products Laboratory</organization>
      <phone>+44 20 8957 2200</phone>
      <email>medinfo@bpl.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

